Quality standards for managing children and adolescents with bronchiectasis: an international consensus.

The global burden of bronchiectasis in children and adolescents is being recognised increasingly. However, marked inequity exists between, and within, settings and countries for resources and standards of care afforded to children and adolescents with bronchiectasis compared with those with other chronic lung diseases. The European Respiratory Society (ERS) clinical practice guideline for the management of bronchiectasis in children and adolescents was published recently. Here we present an international consensus of quality standards of care for children and adolescents with bronchiectasis based upon this guideline. The panel used a standardised approach that included a Delphi process with 201 respondents from the parents and patients' survey, and 299 physicians (across 54 countries) who care for children and adolescents with bronchiectasis. The seven quality standards of care statements developed by the panel address the current absence of quality standards for clinical care related to paediatric bronchiectasis. These internationally derived, clinician-, parent- and patient-informed, consensus-based quality standards statements can be used by parents and patients to access and advocate for quality care for their children and themselves, respectively. They can also be used by healthcare professionals to advocate for their patients, and by health services as a monitoring tool, to help optimise health outcomes.

Informations de copyright

Copyright ©ERS 2022.

Déclaration de conflit d'intérêts

Conflict of interest: E. Alexopoulou, A. Bush, C. Constant, K. Douros, R. Fortescue, M. Griese, A. Hector, B. Karadag, A.T. Hill, A. Kantar, O. Mazulov, F. Midulla, A. Moeller, M. Proesmans, S.T. Yerkovich, A. Zacharasiewicz, Z. Powell, C. Wilson and A.J. Collaro have nothing to disclose. J. Boyd is an employee of the European Lung Foundation. A.B. Chang reports grants from National Health and Medical Research Council, Australia, during the conduct of the study; monies provided to institution from IDMC Membership of unlicensed products (GSK, AstraZeneca), and vaccine (Moderna), other from Advisory member of study design for unlicensed molecules for chronic cough or bronchiectasis (Merck, Zambon, Boehringer Ingelheim); personal fees from being an author of two UpToDate chapters, outside the submitted work. J.D. Chalmers reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, personal fees from Chiesi, grants and personal fees from GlaxoSmithKline, grants from Gilead Sciences, grants and personal fees from Insmed, personal fees from Novartis, personal fees from Zambon, outside the submitted work. J. Grigg reports grants and personal fees from OM Pharma, personal fees from GSK, personal fees from Novartis, personal fees from Omron, personal fees from Astra Zeneca, outside the submitted work. K. Grimwood reports grants from Australian National Health and Medical Research Council and the Australian Medical Research Future Fund during the conduct of the study.